Background And Objective: Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs.
Methods: Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD Assessment Scale-Cognitive subscale (ADAS-Cog) from the baseline to the end of the study.
Results: Of the 300 patients, there were 206 patients in group 1 and 94 patients in group 2. The intention-to-treat group comprised 198 patients (group 1, n = 136; group 2, n = 46) during the 24-week study period. Demographic factors did not differ between group 1 and group 2. There were no significant differences in change in ADAS-cog between group 1 (-0.62±5.70) and group 2 (-0.23±5.98) after the 24-week rivastigmine patch therapy (p = 0.378). The patients in group 1 had a 0.63-point improvement from baseline on the Frontal Assessment Battery, while group 2 had a 0.16-point decline compared to baseline at the end of the study (p = 0.037). The rates of adverse events (AEs) (42.6 vs. 40.3%) and discontinuation due to AEs (10.3% vs. 4.3%) did not differ between the groups.
Conclusions: Although the efficacy and tolerability of rivastigmine patch therapy were not associated with WMH severity in patients with AD, some improvement in frontal function was observed in those with minimal WMHs.
Trial Registration: ClinicalTrials.gov NCT01380288.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546604 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182123 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease.
J Alzheimers Dis
December 2024
Brain Health Unit (CIMES), School of Medicine, University of Málaga, IBIMA, Málaga, Spain.
Background: Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge.
Objective: To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD.
Implantable trilayer microneedle transdermal delivery system to enhance bioavailability and brain delivery of rivastigmine for Alzheimer treatment: A proof-of-concept study.
Eur J Pharm Biopharm
August 2024
Faculty of Pharmacy, Hasanuddin University, Makassar 90245, South Sulawesi, Indonesia. Electronic address:
Alzheimer's disease (ALZ) is a neurological disorder characterized by cognitive decline. Rivastigmine (RV), an acetylcholinesterase inhibitor, is commonly used to treat ALZ. Unfortunately, RV is availablein capsule form, which is associated with low drug bioavailability, and in patch form, which can lead to skin irritation upon repeated use.
View Article and Find Full Text PDFThe donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.
Expert Rev Neurother
June 2024
Department of Psychiatry and Behavioral Neurology, Division of Geriatric Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USA.
Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.
Areas Covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials.
Rivastigmine for the management of anticholinergic delirium.
Clin Toxicol (Phila)
February 2024
Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.
Introduction: Anticholinergic agents are commonly taken in overdose, often causing delirium. The spectrum of anticholinergic delirium ranges from mild agitation to severe behavioural disturbance. Physostigmine is an effective treatment for anticholinergic delirium, but its availability is limited.
View Article and Find Full Text PDFGuidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
J Neurosci Rural Pract
October 2023
Centre for Brain Research, Indian Institute of Science, Bengaluru, Karnataka, India.
Article Synopsis
- The rise in dementia, particularly Alzheimer’s disease (AD), necessitates a deeper understanding of its causes and treatments to enhance patient and caregiver quality of life.
- AD’s pathophysiology involves the buildup of amyloid-beta plaques and tau protein abnormalities, leading to neurotransmitter imbalances that affect brain function.
- FDA-approved treatments for AD can be divided into those addressing behavioral symptoms (like brexpiprazole for agitation) and cognitive decline (such as donepezil, a commonly prescribed cholinesterase inhibitor), each with specific mechanisms and side effects that require monitoring.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!